Vivesto AB and Elevar Therapeutics Inc. announced that the company signed a termination agreement ending the global strategic partnership started in 2020 regarding the commercialization of Vivesto's anticancer product Apealea®. Earlier in 2023, the Elevar Therapeutics said it intended to transfer the rights and obligations of the cancer drug Apealea to a third party. Apealea, which was approved in Europe in 2018, has only been launched in Germany by Elevar's partner Inceptua.

Vivesto will now initiate the transfer of the market authorization holding back to Vivesto, while discussing possible partnerships with other companies interested in licensing Apealea. Vivesto will receive a lump sum of USD 500.000 from Elevar as a one-off compensation to cover costs in the transition of Apealea. All remaining Apealea product inventory has been transferred from Elevar to Vivesto.